The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes Molecular Medicine Springer Nature Link The Hidden Risks of BPC157: What Patients Need to Know About Contamination and Safety Regenexx at New Regeneration Orthopedics ARA 290, BPC 157, TB 500 (16 2 2mg Blend) Liberty Peptides